These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23579660)

  • 1. Genetics: a gene of rare effect.
    Hall SS
    Nature; 2013 Apr; 496(7444):152-5. PubMed ID: 23579660
    [No Abstract]   [Full Text] [Related]  

  • 2. Accelerating the pace of atherosclerosis research.
    Daugherty A; Tabas I; Rader DJ
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):11-2. PubMed ID: 25520521
    [No Abstract]   [Full Text] [Related]  

  • 3. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.
    Le May C; Berger JM; Lespine A; Pillot B; Prieur X; Letessier E; Hussain MM; Collet X; Cariou B; Costet P
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1484-93. PubMed ID: 23559630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New drug development competition for LDL receptor].
    Fujita T
    Nihon Yakurigaku Zasshi; 2014 May; 143(5):262. PubMed ID: 24813799
    [No Abstract]   [Full Text] [Related]  

  • 5. A conversation with Helen Hobbs.
    Hobbs H; Neill US
    J Clin Invest; 2015 Oct; 125(10):3725-6. PubMed ID: 26426073
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
    Guijarro C; Ruilope LM
    Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275
    [No Abstract]   [Full Text] [Related]  

  • 7. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
    Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
    J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomedicine. Lowering LDL--not only how low, but how long?
    Brown MS; Goldstein JL
    Science; 2006 Mar; 311(5768):1721-3. PubMed ID: 16556829
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical use of genetic typing in human lipid disorders.
    Brown WV; Breslow J; Ballantyne C
    J Clin Lipidol; 2012; 6(3):199-207. PubMed ID: 22658144
    [No Abstract]   [Full Text] [Related]  

  • 10. PCSK9: a promising therapeutic target for dyslipidemias?
    Lambert G; Krempf M; Costet P
    Trends Endocrinol Metab; 2006 Apr; 17(3):79-81. PubMed ID: 16487721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monogenic hypercholesterolemias: new genes, new drug targets].
    Mandel'shtam MIu; Vasil'ev VB
    Genetika; 2008 Oct; 44(10):1309-16. PubMed ID: 19062528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PCSK9: is this the way forward for managing residual risk?
    Chowdhury SR; Rees A
    Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations.
    Mayne J; Ooi TC; Raymond A; Cousins M; Bernier L; Dewpura T; Sirois F; Mbikay M; Davignon J; Chrétien M
    Lipids Health Dis; 2013 May; 12():70. PubMed ID: 23663650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preserved adrenal function in fully PCSK9-deficient subject.
    Cariou B; Benoit I; Le May C
    Int J Cardiol; 2014 Sep; 176(2):499-500. PubMed ID: 25062564
    [No Abstract]   [Full Text] [Related]  

  • 15. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
    Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
    Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
    Lipari MT; Li W; Moran P; Kong-Beltran M; Sai T; Lai J; Lin SJ; Kolumam G; Zavala-Solorio J; Izrael-Tomasevic A; Arnott D; Wang J; Peterson AS; Kirchhofer D
    J Biol Chem; 2012 Dec; 287(52):43482-91. PubMed ID: 23135270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 and its modulation.
    Cui CJ; Li S; Li JJ
    Clin Chim Acta; 2015 Feb; 440():79-86. PubMed ID: 25444750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9.
    Choi S; Aljakna A; Srivastava U; Peterson BR; Deng B; Prat A; Korstanje R
    Lipids Health Dis; 2013 Jul; 12():112. PubMed ID: 23883163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol, racial variation and targeted medicines.
    Topol EJ
    Nat Med; 2005 Feb; 11(2):122-3. PubMed ID: 15692593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.